Enhancement of Hypoxia-Activated Prodrug TH-302 Anti-Tumor Activity by Chk1 Inhibition

BMC Cancer - United Kingdom
doi 10.1186/s12885-015-1387-6
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Evaluation of the “Steal” Phenomenon on the Efficacy of Hypoxia Activated Prodrug TH-302 in Pancreatic Cancer

PLoS ONE
Multidisciplinary
2014English

Imaging Biomarkers to Monitor Response to the Hypoxia-Activated Prodrug TH-302 in the MiaPaCa2 Flank Xenograft Model

Magnetic Resonance Imaging
Nuclear MedicineRadiologyBiomedical EngineeringImagingBiophysics
2012English

Chk1 Targeting Reactivates PP2A Tumor Suppressor Activity in Cancer Cells

Cancer Research
Cancer ResearchOncology
2013English

Scoparone Exerts Anti-Tumor Activity Against DU145 Prostate Cancer Cells via Inhibition of STAT3 Activity

PLoS ONE
Multidisciplinary
2013English

Combined Inhibition of Chk1 and Wee1: In Vitro Synergistic Effect Translates to Tumor Growth Inhibition in Vivo

Cell Cycle
MedicineDevelopmental BiologyCell BiologyMolecular Biology
2012English

Rottlerin Exerts Its Anti-Tumor Activity Through Inhibition of Skp2 in Breast Cancer Cells

Oncotarget
Oncology
2016English

821 Anti-Tumor Activity Induced by Topical Delivery of HSP70iQ435A

Journal of Investigative Dermatology
BiochemistryDermatologyCell BiologyMolecular Biology
2019English

The Unidirectional Hypoxia-Activated Prodrug OCT1002 Inhibits Growth and Vascular Development in Castrate-Resistant Prostate Tumors

Prostate
OncologyUrology
2017English

Engineering a Prostate-Specific Membrane Antigen-Activated Tumor Endothelial Cell Prodrug for Cancer Therapy

Science Translational Medicine
Medicine
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy